Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.70 |
| ▸ | AXL | P30530 | 3/20 | 0.70 |
| ▸ | KDR | P35968 | 3/20 | 0.70 |
| ▸ | MST1R | Q04912 | 3/20 | 0.70 |
| ▸ | FLT3 | P36888 | 2/20 | 0.70 |
| ▸ | JAK2 | O60674 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.70 |
| ▸ | FLT1 | P17948 | 2/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.70 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.70 |
| ▸ | FLT4 | P35916 | 2/20 | 0.70 |
| ▸ | TEK | Q02763 | 2/20 | 0.70 |
| ▸ | BTK | Q06187 | 2/20 | 0.70 |
| ▸ | PLK4 | O00444 | 1/20 | 0.70 |
| ▸ | STK25 | O00506 | 1/20 | 0.70 |
| ▸ | CIT | O14578 | 1/20 | 0.70 |
| ▸ | AURKA | O14965 | 1/20 | 0.70 |
| ▸ | CHUK | O15111 | 1/20 | 0.70 |
| ▸ | MUSK | O15146 | 1/20 | 0.70 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409723 | 1.00 | MET (0.70) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371805 | 1.00 | MET (0.70) | METAXLKDRMST1RFLT3 | |
| Water SCHEMBL2452885 | 0.99 | MET (0.69) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371886 | 0.93 | MET (0.61) | METAXLKDRMST1RFLT3 | |
| SCHEMBL411270 | 0.93 | MET (0.63) | METAXLKDRMST1RFLT3 | |
| SCHEMBL372071 | 0.93 | MET (0.73) | METAXLKDRMST1RFLT3 | |
| SCHEMBL372154 | 0.92 | MET (0.59) | METAXLKDRMST1RFLT3 | |
| SCHEMBL372079 | 0.92 | MET (0.58) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371960 | 0.92 | MET (0.64) | METAXLKDRMST1RFLT3 | |
| SCHEMBL371626 | 0.91 | MET (0.63) | METAXLKDRMST1RFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-113164480-B | Pharmaceutical composition for treating diffuse gastric cancer | 学校法人金泽医科大学 | 2023-11-28 | — | — | CN | disclosed |
| WO-2022180809-A1 | THERAPEUTIC FOR LUNG CANCER THAT HAS ACQUIRED RESISTANCE TO TYPE 1 ANTICANCER DRUGS | 学校法人近畿大学 | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | MET 714/4885AXL 909/4885KDR 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.